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Abstract
Background: Locally advanced prostate cancer is often associated with elevated recurrence rates. Despite the
modest response observed, external-beam radiotherapy has been the preferred treatment for this condition. More
recent evidence from randomised trials has demonstrated clinical benefit with the combined use of androgen
suppression in such cases. The aim of this meta-analysis is to compare the combination of distinct hormone
therapy modalities versus radiotherapy alone for overall survival, disease-free survival and toxicity.
Methods: Databases (MEDLINE, EMBASE, LILACS, Cochrane databases and ClinicalTrials.gov) were scanned for
randomised clinical trials involving radiotherapy with or without androgen suppression in local prostate cancer. The
search strategy included articles published until October 2011. The studies were examined and the data of interest
were plotted for meta-analysis. Survival outcomes were reported as a hazard ratio with corresponding 95%
confidence intervals.
Results: Data from ten trials published from 1988 to 2011 were included, comprising 6555 patients. There was a
statistically significant advantage to the use of androgen suppression, in terms of both overall survival and disease
free survival, when compared to radiotherapy alone. The use of long-term goserelin (up to three years) was the
strategy providing the higher magnitude of clinical benefit. In contrast to goserelin, there were no trials evaluating
the use of other luteinizing hormone-releasing hormone (LHRH) analogues as monotherapy. Complete hormonal
blockade was not shown to be superior to goserelin monotherapy.
Conclusions: Based on the findings of this systematic review, the evidence supports the use of androgen
suppression with goserelin monotherapy as the standard treatment for patients with prostate cancer treated with
radiotherapy, which are at high risk of recurrence or metastases.
Background
Prostate cancer is the second most prevalent neoplasm
and the sixth leading cause of cancer mortality, with an
estimated incidence of 903,500 new cases and 258,400
deaths in 2008 [1]. Historically, the incidence of this
condition had a rapid increase during the early 1990s
with later stabilization. This can be largely explained by
the introduction of prostate specific antigen (PSA) test-
ing, causing a sudden diagnosis boost worldwide. For
the same reason, the distribution of prostate cancer
cases was heterogeneous, with higher rates observed in
the United States, Australia, Norway, Japan, Italy and
others [2]. On the other hand, mortality has been
declining in such countries, probably as a consequence
of recent advances in treatment and support [3].
The advent of improved curative intent therapy for
local disease has been suggested as one of the reasons
for the decrease of prostate cancer deaths in the past
decade. Current strategies for the management of loca-
lized prostate cancer consist of either surgical treatment
or radiotherapy. Until the present, there has been no
accurate comparison coming from randomized clinical
trials evaluating the clinical efficacy of these strategies.
Another reason could be related to response to therapy,
which is highly dependent on other prognostic factors.
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For example, patients classified as low-risk (PSA ≤ 10
ng/ml, Gleason ≤ 6, stage T1c or T2a) and treated with
radiotherapy have better prognosis, with a reported 10
year mortality of 2%, while higher risk patients face
mortality rates ranging from 12% to 30% [4]. On the
other hand, a surgical approach for locally advanced
prostate cancer had shown cure rates of less than 25%
[5]. Therefore, external-beam radiotherapy is usually the
preferred treatment in this setting, due to an acceptable
survival rate [6] and less morbidity than surgery. None-
theless, patients with locally advanced disease have the
worst prognosis and higher chances of relapse [7].
Since the 1970s, the role of androgen deprivation ther-
apy adjuvant to radiotherapy to treat locally advanced
prostate cancer has been investigated [8]. The inhibitory
effect of androgen deprivation on the growth and prolif-
eration of prostate cancer cells is well established. Sev-
eral studies have shown a rapid regression of prostate
cancer after total androgen blockade, leading to
hypothesize that the marked regression observed at the
prostatic level of both malignant and non-malignant tis-
sue may increase radiation efficacy. In decreasing the
tumor size by antiandrogen medication, an optimal dose
of radiation could treat adequately prostate cancer with
less adverse events.
In this context, androgen deprivation therapy has been
a matter of discussion and study as a complementary
treatment for high-risk patients. Evidence in favour of
its use combined with radiotherapy has been described,
with benefit in terms of overall survival [9]. However,
the optimal time for introduction, duration of hormone
therapy, and the type of suppression involved are still
unanswered issues.
In this meta-analysis, the authors intended to sum-
marize all the published data to perform appropriate
comparisons between the different regimens used for
androgen deprivation in patients receiving radiotherapy
for localized or locally advanced prostate cancer.
Methods
Search strategy
Search strategies were performed in relevant electronic
databases, including PubMed/MEDLINE, EMBASE,
LILACS, ClinicalTrials.gov and The Cochrane Library
for randomized studies evaluating radiotherapy with or
without androgen suppression in patients with localized
or locally advanced prostate cancer. Articles published
or presented from January 1966 to October 2011 were
identified. Details of the search strategy used for
PubMed/MEDLINE are described separately (Table 1).
Selection criteria
The purpose of this study was to identify all published
randomised, controlled clinical trials in English, Spanish
or Portuguese, comparing radiotherapy with or without
any androgen suppression (orchiectomy, luteinizing hor-
mone-releasing hormone [LHRH] analogues, peripheral
anti-androgens or estrogenic therapy) in localized (cT1-
2) or locally advanced (T3-4 N0-2 M0) prostate carci-
noma. We included studies that evaluated introduction
of androgen suppression either before, during or after
radiotherapy; and excluded those for which anti-andro-
genic treatment was performed in both arms. Two
researchers (ES, AMC) independently examined the list
of references, as well as article selection.
Data extraction
For identification purposes, the selected trials were
named after their first author and year of publication.
Overall survival (OS), disease-free survival (DFS) and
toxicity were the main outcomes of interest. For contin-
uous variables of survival, we looked for the original
hazard ratios (HR). Whenever data reported were una-
vailable or incomplete for analysis, we attempted to esti-
mate it by applying either the described number of
events and the corresponding p-value for the log-rank
statistic, or by transcription of survival curves as sug-
gested by Parmar and colleagues [10]. In this case, cal-
culations were then made through a spreadsheet
developed by Tierney and colleagues [11].
Statistical analysis and synthesis
Evaluation of possible bias, as described by Sterne and
colleagues [12] was performed by two authors (ADS,
ES). Special focus was given to the availability of infor-
mation about randomization, blinding, allocation con-
cealment, description of dropouts, utilization of an
intention-to-treat (ITT) analysis, and source of funding.
Meta-analyses for this study were conducted with Rev-
Man 5.0 software (Cochrane Collaboration’s Information
Management System). Analyses of data consisted of the
HR for time-to-event outcomes and odds ratio (OR) for
dichotomous variables (adverse events) for which 95%
confidence intervals (CI) were calculated and presented
in forest plots. The diamond at the bottom of the plot
summarizes the best estimate results (the width repre-
senting its corresponding 95% CI). Statistical heteroge-
neity was evaluated with the chi-square test [13], and
expressed using the I2 index, as described by Higgins
and colleagues [14]. If heterogeneity was detected (I2 >
50%), a possible explanation was investigated. The pre-
sence of possible publication bias regarding the first
endpoint (OS) was investigated by a funnel plot.
Results
Search results
From 479 potential studies identified with the search
strategies applied, ten published articles from 1988 to
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Table 1 Description of search terms used (for MEDLINE database)
#1 “goserelin acetate” #55 Prostacur
#2 goserelin #56 Prostica
#3 “ICI-118630” #57 SCH-13521
#4 “ICI 118630” #58 “SCH 13521”
#5 “ICI118630” #59 “SCH13521”
#6 Zoladex #60 Prostogenat
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 #61 Testotard
#8 Leuprorelin #62 Apimid
#9 Enantone #63 #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40
#10 “Leuprolide Acetate” OR #41 OR #42 OR #43
#11 “Leuprolide Monoacetate” OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR
#12 Lupron #50 OR #51 OR #52
#13 “TAP-144” OR #53 OR #54 OR #55 OR #56 OR #57OR #58 OR
#14 “TAP 144” #59 OR #60 OR #61
#15 “TAP144” OR #62
#16 “A-43818” #64 Receptal
#17 “A 43818” #65 Buserelin
#18 “A43818” #66 Bigonist
#19 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 #67 Tiloryth
OR #15 OR #16 OR #17 #68 Profact
OR #18 #69 Suprecur
#20 diethylstilbestrol #70 Suprefact
#21 “Stilbene Estrogen” #71 “HOE-766”
#22 Stilbestrol #72 “HOE 766”
#23 Apstil #73 “HOE766”
#24 Tampovagan #74 #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70
#25 Distilbène OR #71 OR #72 OR #73
#26 Agostilben #75 cyproterone
#27 #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 #76 Androcur
#28 “ICI-176334” #77 Cyprone
#29 “ICI 176334” #78 Cyprostat
#30 Casodex #79 “SH 714”
#31 bicalutamide #80 “SH-714”
#32 Cosudex #81 “SH714”
#33 #28 OR #29 OR #30 OR #31 OR #32 #82 #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81
#34 Niftolid* #83 Orchiectom*
#35 flutamide #84 Castration*
#36 Chimax #85 #83 OR #84
#37 Cytamid #86 prostate
#38 Eulexin* #87 prostatic
#39 Drogenil #88 #86 OR #87
#40 Euflex #89 neoplasm*
#41 Fluken #90 Cancer*
#42 Flulem #91 Tumor*
#43 Flumid #92 Malignan*
#44 Fluta 1A Pharma #93 #89 OR #90 OR #91 OR #92
#45 “Fluta-cell” #94 radiotherap*
#46 “Fluta cell” #95 “external beam radiation”
#47 Flutacell #96 radiation
#48 Flutamin #97 brachitherapy
#49 Flutandrona #98 #94 OR #95 OR #96 OR #97
#50 Flutaplex #99 random*
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2011 were included, comprising 6555 enrolled patients.
The literature search results are summarized in Figure 1.
Concerning the methods of androgenic deprivation
therapy evaluated in these studies, three trials involved
central blockade (through goserelin [15,16] or orchiect-
omy [17]), while four studied combined suppression
with flutamide [18-22], one used peripheral blockade
with bicalutamide [23], and another study reported the
use of estrogenic treatment [8]. Further details on study
design and treatment modalities are described in Tables
2 and 3, respectively.
Overall survival
Data regarding OS was available in nine trials. Only four
presented statistically significant results in favour of
androgen deprivation. The funnel plot analysis per-
formed confirmed the absence of publication bias. Due
to the high overall heterogeneity observed between
trials, we conducted subgroup analyses for more homo-
geneous comparisons.
Overall survival per androgen suppression modality
The use of goserelin combined with radiotherapy was
associated with a 28% reduction of the risk of death (OS
results: HR 0.72, 95% CI 0.60-0.87, P = 0.0008) (Figure
2). Although some heterogeneity was noted (I2 = 50%),
the advantage of hormone therapy was present in all
studies. A probable cause for this could be the diverse
treatment durations leading to distinct clinical efficacy
data.
In two trials [20,21], either goserelin or leuprolide was
combined with flutamide. The high heterogeneity (I2 =
62%) precludes the interpretation of the meta-analysis,
and can be explained by the different inclusion criteria
from the trials.
In case of orchiectomy, one study showed the same
pattern of advantage, yet failed to demonstrate statistical
significance of the benefit (HR 0.62, 95% CI 0.36-1.05, P
= 0.08). This finding may be explained by the small
number of patients included in the analysis.
The use of bicalutamide or estrogenic therapy without
LHRH analogues did not result in evidence of OS bene-
fit (HR 0.85, 95% CI 0.70-1.04, and HR 1.00, 95% CI
0.48-2.07, respectively).
Overall survival according to hormonal blockade (central or
complete)
The analysis of central blockade identified three studies:
two with goserelin and one with orchiectomy. This sub-
group analysis demonstrated that the addition of andro-
gen suppression (defined as central blockade) led to a
39% reduction in the risk of death (HR 0.61, 95% CI
0.47-0.81, P = 0.0005). However, the use of complete
hormonal blockade with peripheral suppressors did not
result in a significant advantage (HR 0.79, 95% CI 0.69-
0.90, P = 0.0003) (Figure 3).
Overall survival according to the duration of therapy
We divided this subgroup in two sections: studies
related to treatment for up to 6 months, and studies
reporting durations of 1 year or more. In both sub-
groups, the use of hormonal therapy was significantly
better, while shorter courses of treatment demon-
strated a 21% reduction in the risk of mortality (HR
0.79, 95% CI 0.69-0.90, P = 0.0003), longer treatment
durations provided benefits of an even greater magni-
tude (HR 0.61, 95% CI 0.47-0.81, P = 0.0005) (Figure
4). The interaction test shows a statistical difference
between these subgroups (I2 = 76%; p = 0.04%).
Disease-free survival
In the studies related to orchiectomy and estrogenic
treatment, DFS information was unavailable. Regarding
the available data, similar to the OS analysis, high het-
erogeneity was present for DFS evaluation. Therefore,
479   Publications retrieved       
          from database search 
36   Randomised clinical 
trials  selected for full 
review 
443 Excluded 
26       Excluded 
 21 with hormone therapy in 
both arms 
 3 duplicated data 
 2 did not use radiotherapy 
10      Randomised clinical                      
trials included 
Figure 1 Selection Results. QUOROM flowchart of the systematic
literature review.
Table 1 Description of search terms used (for MEDLINE database) (Continued)
#51 Flutexin #100 #7 AND #19 AND #27 AND #33 AND #63 AND #74
#52 Fugerel AND #82 AND #85 AND
#53 Grisetin #88 AND #93 AND #98 AND #99
#54 Oncosal
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subgroup analyses were performed to better understand
the results, though statistically significant advantages
were observed in all individual trials.
Disease-free survival per androgen suppression modality
The use of goserelin demonstrated an absolute reduc-
tion in recurrence of 47% (HR 0.53, 95% CI 0.43-0.65, P
< 0.00001) (Figure 5). Similar to findings previously
detected in the OS analysis, high heterogeneity was
observed for this outcome (I2 = 74%). The main font of
heterogeneity was the shortest-term blockade arm (3
month) of Denham’s study. Excluding this trial, the het-
erogeneity becomes acceptable (I2 = 50%) and the
reduction on recurrence associated with goserelin was
more pronounced (HR 0.49, 95% CI 0.42-0.58, P <
0.00001).
Two studies analyzed the association of both goserelin
and leuprolide to flutamide, also demonstrating benefit in
DFS as well (HR 0.48, 95% CI 0.30-0.77, P = 0.002). One
study evaluated the association of leuprolide to flutamide,
with a significant benefit to patients receiving hormonal
therapy (HR 0.55, 95% CI 0.34-0.90, P = 0.02). Additionally,
an advantage to hormone therapy was observed also in the
single study with bicalutamide (HR 0.61, 95% CI 0.52-0.72,
P = 0.00001). Further details are described in Figure 5.
Disease-free survival according to hormonal blockade
(central or complete)
Two trials reported data regarding central blockade with
goserelin (Figure 6), from which the meta-analysis
showed benefit from the use of hormone therapy, redu-
cing the risk of relapse in 57% (HR 0.43, 95% CI 0.37-
Table 3 Designed therapies
Author Year Radiotherapy (dose) Hormone Therapy Duration N Median follow up
Zagars 1988 70 Gy Diethylstilbestrol 25 mg PO qd Continuously 82 14.5 years






Lawton 2005 65 to 70 Gy Goserelin 3.6 mg/month Continuously 977 6.5 years
Granfors 2006 60 to 70 Gy Orchiectomy Permanent 91 9.7 years
See 2006 NS Bicalutamide 150 mg PO qd Decided by investigator 1370 7.2 years
D’Amico 2008 NS Goserelin 3,6 mg or
Leuprolide 7.5 mg/month +
Flutamide
6 months 206 8.2 years
Roach 2008 65 to 70 Gy Goserelin 3.6 mg/month + Flutamide 3 months 456 11.9 years
Bolla 2010 70 Gy Goserelin 3.6 mg/month 3 years 415 9.1 years






Jones 2011 66.6 Gy Goserelin 3,6 mg or
Leuprolide 7.5 mg/month +
Flutamide
4 months 1979 9.1 years
Abbreviations: Gy Gray unit, N number of patients, NS not stated, PO oral administration, qd every day
Table 2 Methodological characteristics of clinical trials
Author Year Rand. Alloc. Blind. Desc. losses Sample Size ITT Multic. Sponsor
Zagars 1988 NS NS No Yes No No No Public
Laverdiere 2004 NS NS No No No Ns No NS
Lawton 2005 Yes Yes No Yes Yes No Yes NS
Granfors 2006 NS NS No Yes Yes Yes No Public
See 2006 Yes Yes Yes Yes Yes Yes Yes Industry
D’Amico 2008 Yes Yes No Yes Yes Yes Yes Public
Roach 2008 NS NS No Yes Yes Yes Yes Public
Bolla 2010 Yes Yes No Yes Yes Yes Yes Both
Denham 2011 Yes Yes No Yes Yes No No Both
Jones 2011 Yes Yes No Yes Yes Yes Yes Public
Abbreviations: Alloc allocation concealment, Blind blinding, Desc. Losses description of losses to follow-up, ITT intention-to-treat analysis, Multic multicentric, NS
not stated, Rand adequate randomization method, Sample Size adequate planning and calculation of sample size
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0.49, P < 0.00001). As with complete blockade with the
combination of flutamide, the gain for DFS appeared to
be similar to that observed for isolated goserelin (HR
0.57, 95% CI 0.51-0.65, P < 0.00001).
Disease-free survival according to the duration of therapy
The treatment with androgen suppression for a period
not longer than 6 months (Figure 7) demonstrated the
reduction of 43% in the risk of relapse (HR 0.57, 95% CI
0.50-0.65, P < 0.00001). Three other studies evaluated
the duration of more than 1 year of therapy, with
greater benefits, with a reduction of 57% in the risk of
relapse (HR 0.43, 95% CI 0.38-0.50, P < 0.00001).
Toxicity
Unfortunately, data extraction was compromised for this
outcome as a consequence of poor reporting of adverse
events among trials. Nonetheless, when trials were ana-
lysed individually, there were apparently no reports of
increased toxicity.
Discussion
An overall conclusion of this review and meta-analysis is
that androgen deprivation therapy can be significantly
beneficial for patients in terms of DFS and OS, when
combined with radiotherapy. Nevertheless, many strate-
gies for suppression have been studied so far, with con-
flicting results regarding efficacy and tolerability.
Estrogen therapy in high doses seems to be linked
with higher risks of cardiovascular and thromboembolic
events [24], but more importantly, failed to produce
benefit in a small, single trial of 84 patients. The trials
evaluating the performance of orchiectomy indicated a
Figure 2 Overall Survival per Androgen Suppression Meta-analysis. Meta-analysis of overall survival, comparing hormone therapy combined
with radiotherapy versus radiotherapy alone in patients with non-metastatic prostate cancer (Note: In the study by D’Amico, most patients
received Leuprolide). Abbreviations: CI = confidence interval; HT–hormone therapy; IV = Generic Inverse Variance; RT–radiotherapy; SE = standard
error.
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Figure 3 Overall Survival According to Hormonal Blockade Meta-analysis. Meta-analysis of overall survival, comparing central androgen
deprivation (goserelin or orchiectomy) or complete hormonal blockade (LHRH analogues plus flutamide) combined with radiotherapy versus
radiotherapy alone in patients with non-metastatic prostate cancer. Abbreviations: CI = confidence interval; HT–hormone therapy; IV = Generic
Inverse Variance; RT–radiotherapy; SE = standard error.
Figure 4 Overall Survival According to Treatment Duration Meta-analysis. Meta-analysis of overall survival, comparing hormone therapy
combined with radiotherapy versus radiotherapy alone in patients with non-metastatic prostate cancer, according to the time of hormone
treatment (up to 6 months versus one year or more). Abbreviations: CI = confidence interval; HT–hormone therapy; IV = Generic Inverse
Variance; RT–radiotherapy; SE = standard error.
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possible advantage to its use, though lacking statistical
significance. For the reasons stated, we concluded that
there is no evidence so far, to support the use of definite
deprivation for such patients, nor accurate analyses of
possible long-term toxicity. Hence, current studies point
toward androgen suppression with LHRH analogues as
more advantageous in these cases. Until the present
time, goserelin was the most studied compound in this
category. Further studies are warranted to demonstrate
a similar benefit from other types of analogues. Addi-
tionally, combination therapy with peripheral blockade
did not offer a major benefit in comparison to goserelin
monotherapy.
There is still much discussion about the comparison
of LHRH analogues to surgical castration regarding tes-
tosterone levels. Chemical androgen deprivation is
reported to be similar among the different types of ana-
logues used, although there is fear that sudden eleva-
tions in the level of testosterone, according to distinct
pharmacodynamic characteristics, could interfere with
treatment and ultimately compromise survival [25].
Authors of a recent systematic review did not provide
evidence of such a presumed effect from the analogues
used in practice [26].
Our study also suggested that longer androgen sup-
pression results in better DFS and OS. Those observa-
tions are in accordance to a previous systematic review
focusing the duration of deprivation therapy [27], and a
randomized clinical trial comparing 6 months versus 2
years of treatment [28].
Some limiting factors in this meta-analysis must be
highlighted. There were different schedules of treatment
resulting in the high heterogeneity described and the
distinct patient selection criteria applied from each
investigator. One example is the trial from Bolla and
colleagues [16], presenting the greatest reported benefit
in survival with the use of 3 years of goserelin after
completion of radiotherapy. Though statistically
Figure 5 Disease Free Survival per Androgen Suppression Meta-analysis. Meta-analysis of disease-free survival, comparing hormone therapy
combined with radiotherapy versus radiotherapy alone in patients with non-metastatic prostate cancer. Abbreviations: CI = confidence interval;
HT–hormone therapy; IV = Generic Inverse Variance; RT–radiotherapy; SE = standard error.
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Figure 6 Disease Free Survival According to Hormonal Blockade Meta-analysis. Meta-analysis of disease-free survival, comparing androgen
deprivation (goserelin or orchiectomy) or complete hormonal blockade (combination of flutamide) combined with radiotherapy versus
radiotherapy alone in patients with non-metastatic prostate cancer. Abbreviations: CI = confidence interval; HT–hormone therapy; IV = Generic
Inverse Variance; RT–radiotherapy; SE = standard error.
Figure 7 Disease Free Survival According to Treatment Duration Meta-analysis. Meta-analysis of disease-free survival, comparing hormone
therapy combined with radiotherapy versus radiotherapy alone in patients with non-metastatic prostate cancer, according to the time of
hormone treatment (up to 6 months versus 1 year or more). Abbreviations: CI = confidence interval; HT–hormone therapy; IV =Generic Inverse
Variance; RT–radiotherapy; SE = standard errors.
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significant data were favourable for the use of such a
protocol, there are still questions concerning the defini-
tion of high-risk patients in this study (T1 or T2 with
histological grades greater than 3, or T3 and T4 with
any grade). Distinct criteria among studies have limited
the possibility to identify, with great accuracy, the
groups expected to benefit from androgen suppression.
Moreover, there has been some discussion involving
the type of radiotherapy performed, with the hypothesis
that either conformational or intensity modulated treat-
ments - by delivering higher doses of radiotherapy -
could reduce the necessity of androgen deprivation. This
idea, however, was not proven in randomised clinical
trials for high-risk patients. In low-risk prostate cancer,
one prospective randomised study compared conforma-
tional versus standard external beam radiotherapy, and
described a reduction of biochemical relapse from 32%
to 17%, without impact on overall survival [29].
Toxicity analyses were impeded by scarce reports of
adverse events in the published articles. Results from
observational studies have suggested the possibility that
long-term androgen suppression might be related to a
higher risk of metabolic syndrome [30] and osteoporosis
[31], despite the lack of such descriptions in prospective
work. Taking into account the tendency of higher effi-
cacy with a longer duration of therapy, as shown in our
analysis, such knowledge should be important in future
trials.
Conclusions
This meta-analysis was able to demonstrate a benefit
from the combination of androgen deprivation therapy
and external-beam radiotherapy for high-risk prostate
cancer patients. The use of goserelin for a period longer
than 1 year was associated with more beneficial survival
outcomes, and should be considered standard treatment
for those with higher risk of relapse. At this time, there
is insufficient evidence to support other LHRH analo-
gues or identify possible limiting long-term toxicities.
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